17/05 | APREA THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Completion of Acqui.. |  |
17/05 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to NASDAQ Composite Index |  |
16/05 | APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a.. |  |
16/05 | TRANSCRIPT : Aprea Therapeutics, Inc. - Special Call |  |
16/05 | APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di.. |  |
16/05 | Aprea Therapeutics Announces Acquisition of Atrin Pharmaceuticals Inc. and Reports Firs.. |  |
16/05 | Aprea Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31,.. |  |
16/05 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from NASDAQ Composite Index |  |
16/05 | ATRIN PHARMACEUTICALS LLC ACQUIRED A : APRE) in a reverse merger transaction. |  |
15/03 | APREA THERAPEUTICS : Reports Fourth Quarter and Full Year 2021 Financial Results and Provi.. |  |
15/03 | APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a.. |  |
15/03 | Aprea Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, .. |  |
15/03 | Aprea Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Prov.. |  |
15/03 | Aprea Therapeutics, Inc. Provides Update on Business Operations |  |
15/03 | Aprea Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December.. |  |
13/01 | TRANSCRIPT : Aprea Therapeutics, Inc. Presents at JPMorgan 40th Annual Healthcare Conferen.. |  |
13/01 | APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Regulation FD Di.. |  |
06/01 | Aprea Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference on T.. |  |
2021 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from NASDAQ Biotechnology Index |  |
2021 | Recap and Update of Positive Data from Three Presentations in Patients with TP53 Mutant.. |  |
2021 | Aprea Therapeutics Presents Primary Analysis from Phase 2 Trial of Eprenetapopt + Azaci.. |  |
2021 | Aprea Therapeutics, Inc. Announces Updated Results from Its Phase 2 Trial Evaluating Ep.. |  |
2021 | APREA THERAPEUTICS : Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid Ma.. |  |
2021 | APREA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) |  |
2021 | Aprea Therapeutics Says FDA Has Removed Its Clinical Hold on Study of Eprenetapopt for .. |  |
2021 | APREA THERAPEUTICS : FDA Lifts Hold on Eprenetapopt Study in Lymphoid Malignancies |  |
2021 | Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid M.. |  |
2021 | Aprea Therapeutics Announces Removal of FDA Clinical Hold on Eprenetapopt in Lymphoid M.. |  |
2021 | Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on .. |  |
2021 | APREA THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition a.. |  |
2021 | Aprea Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months.. |  |
2021 | Aprea Therapeutics Reports Third Quarter 2021 Financial Results and Provides Update on .. |  |
2021 | Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd.. |  |
2021 | Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd.. |  |
2021 | Aprea Therapeutics to Present Data from Clinical Trials Evaluating Eprenetapopt at 63rd.. |  |
2021 | INSIDER SELL : Aprea Therapeutics |  |
2021 | APREA THERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K) |  |
2021 | Aprea Therapeutics, Inc. Announces Resignation of Johan Christenson from the Board of D.. |  |
2021 | INSIDER SELL : Aprea Therapeutics |  |
2021 | INSIDER SELL : Aprea Therapeutics |  |
2021 | INSIDER SELL : Aprea Therapeutics |  |
2021 | INSIDER SELL : Aprea Therapeutics |  |
2021 | APREA THERAPEUTICS : Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) in Advan.. |  |
2021 | Aprea Therapeutics, Inc. Presents Data From Phase 1/2 Trial of Eprenetapopt (APR-246) i.. |  |
2021 | Top Premarket Gainers |  |
2021 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from S&P Global BMI Index |  |
2021 | APREA THERAPEUTICS : to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Soli.. |  |
2021 | Aprea Therapeutics to Present Data from Phase 1/2 Trial of Eprenetapopt in Advanced Sol.. |  |
2021 | NORTH AMERICAN MORNING BRIEFING : Stock Furures -3- |  |
2021 | NORTH AMERICAN MORNING BRIEFING : Weak Chinese -4- |  |
2021 | APREA THERAPEUTICS : Management's Discussion and Analysis of Financial Condition and Resul.. |  |
2021 | APREA THERAPEUTICS : Reports Second Quarter 2021 Financial Results and Provides Update on .. |  |
2021 | APREA THERAPEUTICS, INC. : Results of Operations and Financial Condition, Other Events, Fi.. |  |
2021 | Aprea Therapeutics, Inc. Reports Unaudited Consolidated Earnings Results for the Second.. |  |
2021 | Aprea Therapeutics Reports Second Quarter 2021 Financial Results and Provides Update on.. |  |
2021 | APREA THERAPEUTICS : Says FDA Places Clinical Hold on Lymphoid Malignancy Program |  |
2021 | Aprea Therapeutics Announces Clinical Hold on Lymphoid Malignancy Program |  |
2021 | Aprea Therapeutics, Inc. Announces Clinical Hold on Lymphoid Malignancy Program |  |
2021 | APREA THERAPEUTICS : FDA Puts Clinical Hold on Lymphoid Malignancy Program |  |
2021 | SECTOR UPDATE : Health Care Pulls Back Ahead of Friday Opener |  |
2021 | TRANSCRIPT : Aprea Therapeutics, Inc. - Special Call |  |
2021 | Aprea Therapeutics Announces a Partial Clinical Hold on Myeloid Malignancy Programs |  |
2021 | APREA THERAPEUTICS, INC. : Other Events, Financial Statements and Exhibits (form 8-K) |  |
2021 | APREA THERAPEUTICS : Announces a Partial Clinical Hold on Myeloid Malignancy Programs |  |
2021 | APREA THERAPEUTICS : Phase 2 Trial of Eprenetapopt With Azacitidine Yields Positive Result.. |  |
2021 | APREA THERAPEUTICS : Announces Positive Results from Phase 2 Trial of Eprenetapopt + Azaci.. |  |
2021 | Aprea Therapeutics, Inc. Announces Positive Results from Phase 2 Trial of Eprenetapopt .. |  |
2021 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2500 Index |  |
2021 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2000 Growth Index |  |
2021 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 3000 Growth Index |  |
2021 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2500 Growth Index |  |
2021 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 3000E Index |  |
2021 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to Russell 3000E Value Index |  |
2021 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) added to Russell Microcap Value Index |  |
2021 | APREA THERAPEUTICS, INC.(NASDAQGS : APRE) dropped from Russell 2000 Dynamic Index |  |